Aims To quantify usage of COX‐2 inhibitors compared with nonselective NSAIDs and to
determine their impact (including financial) on the co‐prescription of antipeptic ulcer (anti …

Background Non-steroidal anti inflammatory drugs (NSAIDs) are thought to account for
almost 25% of all reported adverse drug reactions, primarily gastrointestinal (GI) toxicity …

Purpose Rofecoxib and celecoxib have been recently introduced and promoted as
'safer'non‐steroidal anti‐inflammatory drugs (NSAIDs) regarding gastric toxicity. The primary …

Objective: To identify factors that influence prescribers in their selection and use of cyclo-
oxygenase-2 (COX-2) selective inhibitors as opposed to non-selective non-steroidal anti …

Purpose To assess the relative incidence of peptic ulcer bleeding and perforation (PUBP) in
users of selective cyclooxygenase‐2 (COX‐2) inhibitors and nonselective nonsteroidal anti …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Cyclooxygenase‐2 (COX‐2)
inhibitors are selective nonsteroidal anti‐inflammatory drugs (NSAIDs), purported to …

This pharmacoepidemiologic study was conducted to determine whether risk factors for
upper gastrointestinal bleeding influenced the prescription of cyclo-oxygenase (COX)-2 …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Cyclo‐oxygenase‐2 (COX‐2)
inhibitors were marketed aggressively and their rapid uptake caused safety concerns and …

Purpose To compare hospitalization rates for serious upper and lower gastrointestinal (GI)
events between chronic and acute users of a traditional non‐steroidal anti‐inflammatory …

What is already known about this subject• Prior to the worldwide withdrawal of rofecoxib in
2004, due to cardiovascular toxicity with its use, selective COX‐2 inhibitors had been shown …